272 related articles for article (PubMed ID: 28275964)
1. Reversal of threatening blindness after initiation of eculizumab in Purtscher-like retinopathy secondary to atypical hemolytic uremic syndrome.
Ramos de Carvalho JE; Schlingemann RO; Oranje M; Bemelman FJ; van Schooneveld MJ
Int Ophthalmol; 2018 Feb; 38(1):399-407. PubMed ID: 28275964
[TBL] [Abstract][Full Text] [Related]
2. Optic coherence tomography angiography follow-up in a case of Purtscher-like retinopathy due to atypical hemolytic uremic syndrome.
Santamaría Álvarez JF; Serret Camps A; Aguayo Alvarez J; García García O
Eur J Ophthalmol; 2020 May; 30(3):NP14-NP17. PubMed ID: 30841747
[TBL] [Abstract][Full Text] [Related]
3. PURTSCHER-LIKE RETINOPATHY ASSOCIATED WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME: CASE REPORT AND REVIEW OF OUTCOMES.
Gange WS; Haghighi A; Toy BC
Retin Cases Brief Rep; 2023 Mar; 17(2):154-159. PubMed ID: 33492076
[TBL] [Abstract][Full Text] [Related]
4. [Retinal tomography features of thrombotic microangiopathy associated with atypical hemolytic-uremic syndrome].
Smirnova TV; Kazaryan EE; Sheludchenko VM
Vestn Oftalmol; 2022; 138(4):20-28. PubMed ID: 36004587
[TBL] [Abstract][Full Text] [Related]
5. [Ocular thrombotic microangiopathy in atypical hemolytic-uremic syndrome (a clinical case study)].
Smirnova TV; Sheludchenko VM; Kozlovskaya NL; Kazaryan EE; Andzhelova DV; Sherstneva LV; Velieva IA; Kuchieva AM; Akaeva MI
Vestn Oftalmol; 2018; 134(5. Vyp. 2):215-226. PubMed ID: 30499520
[TBL] [Abstract][Full Text] [Related]
6. Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury.
Cao M; Leite BN; Ferreiro T; Calvo M; Fernández C; Alonso Á; Rodriguez A; Salvador P; Seijo R; Pita S; Arjona E; Rodríguez de Córdoba S; Valdés Cañedo F
Am J Nephrol; 2018; 48(3):225-233. PubMed ID: 30205388
[TBL] [Abstract][Full Text] [Related]
7. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
[TBL] [Abstract][Full Text] [Related]
8. Purtscher-Like Retinopathy Associated with Atypical Hemolytic Uremic Syndrome.
Ustaoğlu M; Önder F; Solmaz N; Öztürk S; Ayer M
Turk J Ophthalmol; 2017 Dec; 47(6):348-350. PubMed ID: 29326853
[TBL] [Abstract][Full Text] [Related]
9. [Optical coherence tomography angiography in the diagnosis of retinal microangiopathy in atypical hemolytic-uremic syndrome (a case report)].
Smirnova TV; Kozlovskaya NL; Sheludchenko VM; Budzinskaya MV
Vestn Oftalmol; 2020; 136(4. Vyp. 2):226-234. PubMed ID: 32880144
[TBL] [Abstract][Full Text] [Related]
10. Ocular involvement in atypical haemolytic uraemic syndrome.
Sampedro López A; Domínguez Moro B; Baltar Martin JM; Garcia Monteavaro C; Barbón García JJ
Arch Soc Esp Oftalmol; 2017 Dec; 92(12):594-597. PubMed ID: 28347544
[TBL] [Abstract][Full Text] [Related]
11. Hypertensive choroidopathy in atypical hemolytic-uremic syndrome.
Polito MS; Machetta F; Fea AM; Eandi CM
Eur J Ophthalmol; 2021 Mar; 31(2):NP63-NP66. PubMed ID: 31875682
[TBL] [Abstract][Full Text] [Related]
12. An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.
Sengul Samanci N; Ayer M; Ergen A; Ozturk S
Transfus Apher Sci; 2015 Jun; 52(3):314-6. PubMed ID: 25634788
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.
Ito N; Hataya H; Saida K; Amano Y; Hidaka Y; Motoyoshi Y; Ohta T; Yoshida Y; Terano C; Iwasa T; Kubota W; Takada H; Hara T; Fujimura Y; Ito S
Clin Exp Nephrol; 2016 Apr; 20(2):265-72. PubMed ID: 26156042
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
Gediz F; Payzin BK; Ecemis S; Güler N; Yilmaz AF; Topcugil F; Berdeli A
Transfus Apher Sci; 2016 Dec; 55(3):357-362. PubMed ID: 27742267
[TBL] [Abstract][Full Text] [Related]
15. Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab.
Gately R; San A; Kurtkoti J; Parnham A
Nephrology (Carlton); 2017 Feb; 22 Suppl 1():32-35. PubMed ID: 28176475
[TBL] [Abstract][Full Text] [Related]
16. Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome.
Cavero T; Arjona E; Soto K; Caravaca-Fontán F; Rabasco C; Bravo L; de la Cerda F; Martín N; Blasco M; Ávila A; Huerta A; Cabello V; Jarque A; Alcázar C; Fulladosa X; Carbayo J; Anaya S; Cobelo C; Ramos N; Iglesias E; Baltar J; Martínez-Gallardo R; Pérez L; Morales E; González R; Macía M; Draibe J; Pallardó L; Quintana LF; Espinosa M; Barros X; Pereira F; Cao M; Moreno JA; Rodríguez de Córdoba S; Praga M;
Kidney Int; 2019 Oct; 96(4):995-1004. PubMed ID: 31420192
[TBL] [Abstract][Full Text] [Related]
17. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
Fakhouri F; Delmas Y; Provot F; Barbet C; Karras A; Makdassi R; Courivaud C; Rifard K; Servais A; Allard C; Besson V; Cousin M; Châtelet V; Goujon JM; Coindre JP; Laurent G; Loirat C; Frémeaux-Bacchi V
Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
[TBL] [Abstract][Full Text] [Related]
18. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
Diamante Chiodini B; Davin JC; Corazza F; Khaldi K; Dahan K; Ismaili K; Adams B
Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
[TBL] [Abstract][Full Text] [Related]
19. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
[TBL] [Abstract][Full Text] [Related]
20. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
Mallett A; Hughes P; Szer J; Tuckfield A; Van Eps C; Cambell SB; Hawley C; Burke J; Kausman J; Hewitt I; Parnham A; Ford S; Isbel N
Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
